NO20001171L - FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister - Google Patents

FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister

Info

Publication number
NO20001171L
NO20001171L NO20001171A NO20001171A NO20001171L NO 20001171 L NO20001171 L NO 20001171L NO 20001171 A NO20001171 A NO 20001171A NO 20001171 A NO20001171 A NO 20001171A NO 20001171 L NO20001171 L NO 20001171L
Authority
NO
Norway
Prior art keywords
naturally occurring
procedure
bone volume
increasing bone
selective agonists
Prior art date
Application number
NO20001171A
Other languages
English (en)
Other versions
NO20001171D0 (no
Inventor
James Richard Hartke
Mark Walden Lundy
Mitchell Anthony Delong
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20001171D0 publication Critical patent/NO20001171D0/no
Publication of NO20001171L publication Critical patent/NO20001171L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet nye metoder for å øke benvolum omfattende å administrere en ikke-naturlig forekommende FP-agonist til et individ som har behov for slik behandling. Det er videre beskrevet en fremgangsmåte ved behandling eller forebygging av bensykdommer omfattende å administrere en ikke-naturlig forekommende FP-agonist til et individ som har behov for slik behandling.
NO20001171A 1997-09-09 2000-03-07 FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister NO20001171L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5830697P 1997-09-09 1997-09-09
PCT/US1998/018338 WO1999012551A1 (en) 1997-09-09 1998-09-04 Method of increasing bone volume using non-naturally-occurring fp selective agonists

Publications (2)

Publication Number Publication Date
NO20001171D0 NO20001171D0 (no) 2000-03-07
NO20001171L true NO20001171L (no) 2000-05-09

Family

ID=22015996

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001171A NO20001171L (no) 1997-09-09 2000-03-07 FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister

Country Status (20)

Country Link
US (1) US6156799A (no)
EP (1) EP1045694A1 (no)
JP (1) JP2001515864A (no)
KR (1) KR20010023840A (no)
CN (1) CN1269721A (no)
AR (1) AR013479A1 (no)
AU (1) AU739275B2 (no)
BR (1) BR9811780A (no)
CA (1) CA2303800A1 (no)
CO (1) CO4980882A1 (no)
HU (1) HUP0004581A2 (no)
ID (1) ID24827A (no)
IL (1) IL134760A0 (no)
NO (1) NO20001171L (no)
PE (1) PE119099A1 (no)
PL (1) PL339288A1 (no)
SK (1) SK3412000A3 (no)
TR (1) TR200000662T2 (no)
WO (1) WO1999012551A1 (no)
ZA (1) ZA988228B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
US6451859B1 (en) * 1999-03-05 2002-09-17 The Procter & Gamble Company C16 unsaturated FP-selective prostaglandins analogs
CA2366755A1 (en) * 1999-03-05 2000-09-08 The Procter & Gamble Company Method of increasing bone volume using non-naturally-occurring ep, selective agonists
EP1159266B1 (en) * 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
CA2303060A1 (en) * 1999-04-14 2000-10-14 United States Gear Corporation Towed vehicle brake controller
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7467892B2 (en) 2000-08-29 2008-12-23 Imaging Therapeutics, Inc. Calibration devices and methods of use thereof
US6904123B2 (en) 2000-08-29 2005-06-07 Imaging Therapeutics, Inc. Methods and devices for quantitative analysis of x-ray images
AU8689201A (en) 2000-08-29 2002-03-13 Osteonet Com Inc Methods and devices for quantitative analysis of x-ray images
US7660453B2 (en) 2000-10-11 2010-02-09 Imaging Therapeutics, Inc. Methods and devices for analysis of x-ray images
US8639009B2 (en) 2000-10-11 2014-01-28 Imatx, Inc. Methods and devices for evaluating and treating a bone condition based on x-ray image analysis
US8000766B2 (en) 2001-05-25 2011-08-16 Imatx, Inc. Methods to diagnose treat and prevent bone loss
CA2454584C (en) * 2001-07-23 2009-09-22 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient
CN1893977B (zh) * 2001-07-23 2012-12-05 小野药品工业株式会社 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物
EP1478314A2 (en) * 2002-02-07 2004-11-24 Rutgers, The State University Of New Jersey Therapeutical polyanhydride compounds for drug delivery
US8965075B2 (en) 2002-09-16 2015-02-24 Imatx, Inc. System and method for predicting future fractures
US7840247B2 (en) 2002-09-16 2010-11-23 Imatx, Inc. Methods of predicting musculoskeletal disease
WO2004086972A2 (en) 2003-03-25 2004-10-14 Imaging Therapeutics, Inc. Methods for the compensation of imaging technique in the processing of radiographic images
US8290564B2 (en) 2003-09-19 2012-10-16 Imatx, Inc. Method for bone structure prognosis and simulated bone remodeling
WO2005027732A2 (en) * 2003-09-19 2005-03-31 Imaging Therapeutics, Inc. Method for bone structure prognosis and simulated bone remodeling
EP1789924A2 (en) 2004-09-16 2007-05-30 Imaging Therapeutics, Inc. System and method of predicting future fractures
WO2008034101A2 (en) * 2006-09-15 2008-03-20 Imaging Therapeutics, Inc. Method and system for providing fracture/no fracture classification
US8939917B2 (en) 2009-02-13 2015-01-27 Imatx, Inc. Methods and devices for quantitative analysis of bone and cartilage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
WO1993015767A1 (en) * 1992-02-05 1993-08-19 Merck & Co., Inc. Implant therapy for bone growth stimulation
US5310759A (en) * 1992-08-12 1994-05-10 Bockman Richard S Methods of protecting and preserving connective and support tissues
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5747660A (en) * 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists

Also Published As

Publication number Publication date
EP1045694A1 (en) 2000-10-25
KR20010023840A (ko) 2001-03-26
CO4980882A1 (es) 2000-11-27
CN1269721A (zh) 2000-10-11
AU9219298A (en) 1999-03-29
HUP0004581A2 (hu) 2001-05-28
PL339288A1 (en) 2000-12-04
PE119099A1 (es) 2000-02-03
AR013479A1 (es) 2000-12-27
WO1999012551A1 (en) 1999-03-18
SK3412000A3 (en) 2000-12-11
ID24827A (id) 2000-08-24
JP2001515864A (ja) 2001-09-25
BR9811780A (pt) 2000-09-12
CA2303800A1 (en) 1999-03-18
TR200000662T2 (tr) 2000-07-21
US6156799A (en) 2000-12-05
ZA988228B (en) 1999-03-09
IL134760A0 (en) 2001-04-30
AU739275B2 (en) 2001-10-11
NO20001171D0 (no) 2000-03-07

Similar Documents

Publication Publication Date Title
NO20001171L (no) FremgangsmÕte ved økning av benvolum under anvendelse av ikke naturlig forekommende FP-selektive agonister
Stebbins et al. Prostaglandins contribute to cardiovascular reflexes evoked by static muscular contraction.
Cruwys et al. The role of bradykinin B1 receptors in the maintenance of intra‐articular plasma extravasation in chronic antigen‐induced arthritis
Currie et al. Rod outer segments elongate in constant light: darkness is required for normal shedding
Falabella Repigmentation of leukoderma by minigrafts of normally pigmented, autologous skin
Swope et al. Regulation of cutaneous pigmentation by titration of human melanocytes in cultured skin substitutes grafted to athymic mice
NO934137L (no) Fremgangsmaate for subkutan, suprafascial, pedikulaer, indre fiksering
Munglani et al. Changes in neuronal markers in a mononeuropathic rat model: relationship between neuropeptide Y, pre-emptive drug treatment and long-term mechanical hyperalgesia
Haller et al. Dynamic activation of KATP channels in rhythmically active neurons
Bell et al. The influence of semicarbazide-induced depletion of γ-aminobutyric acid on presynaptic inhibition
Houssay et al. Effects of the pineal gland upon the hair cycles in mice
Okamoto et al. Genistein, a soybean isoflavone, inhibits inward rectifier K+ channels in rat osteoclasts
Corrodi et al. The Effect of Nerve Activity on the Depletion of the Adrenergic Transmitter by Inhibitors of Noradrenaline Synthesis 1
De La Prida et al. Origin of the synchronized network activity in the rabbit developing hippocampus
ATE219929T1 (de) Hautbleichende dermatologische und/oder kosmetische zusammensetzung
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
T O'Shaughnessy et al. A1 adenosine receptor-mediated block of epileptiform activity induced in zero magnesium in rat neocortex in vitro
Chiarello Full‐face cryo‐(liquid nitrogen) peel
Fusi et al. Ca2+ entry blocking and contractility promoting actions of norbormide in single rat caudal artery myocytes
Farnoush et al. Sequential histological changes and mast cell response in skin during chemically‐induced carcinogenesis
Johansson et al. Histaminergic nerves demonstrated in the skin. A new direct mode of neurogenic inflammation?
DK0840607T3 (da) Ny medicinsk anvendelse
NO20014192L (no) Fremgangsmåte ved ökning av benvolum ved å anvende ikke naturlig forekommende EP1-selektive agonister
Miller Inhibitory nerves to insect spiracles
NO984197L (no) FremgangsmÕte for behandling av autisme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application